{name}
{subtitle}
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~21 mi. (Pécs, Hungary, +130 more cities)
facility
Pécsi Tudományegyetem Klinikai Központ-Urológiai Klinika ( Site 1304)
drug
BCG solution, +1 more drug
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~21 mi. (Pécs, Hungary, +207 more cities)
facility
Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 2905)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~21 mi. (Pécs, Hungary, +159 more cities)
facility
Pecsi Tudomanyegyetem AOK ( Site 1009)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
city
~21 mi. (Pécs, Hungary, +150 more cities)
facility
Pecsi Tudomanyegyetem Onkoterapias Intezet ( Site 0452)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~21 mi. (Pécs, Hungary, +137 more cities)
facility
Pecsi Tudomanyegyetem AOK ( Site 0501)
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~21 mi. (Pécs, Hungary, +145 more cities)
facility
Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2314)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
city
~21 mi. (Pécs, Hungary, +59 more cities)
facility
Pécsi Tudományegyetem Klinikai Központ
biomarker
BRAF V600E, +1 more biomarker
drug
binimetinib, +2 more drugs
drug type
immunotherapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~57 mi. (Kaposvár, Hungary, +140 more cities)
facility
Somogy Megyei Kaposi Mór Oktató Kórház-Oncology center ( Site 0267)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~57 mi. (Kaposvár, Hungary, +199 more cities)
facility
Somogy Megyei Kaposi Mór Oktató Kórház-Oncology center ( Site 0484)